RenovoRx, Inc.

NasdaqCM RNXT

RenovoRx, Inc. Current Liabilities for the quarter ending September 30, 2024

RenovoRx, Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: RNXT

RenovoRx, Inc.

CEO	Mr. Shaun R. Bagai
IPO Date	Aug. 26, 2021
Location	United States
Headquarters	4546 El Camino Real
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Key trends

Past 5 years